PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Nanjing Legend Biotech Co., Ltd

USPTO PatentsView assignee record - 16 granted patents across 5 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Nanjing ranks #17,924 of 49,997 tracked US assignees by granted-patent volume, with 16 patents across 5 technology areas.

#17,924
of 49,997 US assignees by volume
Top 13%
by Innovation Score (50.5/100)
21.3
avg claims per patent
+1300%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R17924 · Foreign Corporation #17,924 · 16 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-MICRO 16 grants
  • MID-PACK #17,924/49,997
  • PHOTO-FINISH Namuga
  • CPC-NARROW C07K · 5 areas
  • INNOV-PAR 50.5/100
  • CLAIMS-DENSE 21.3 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-SURGE +1300% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Namuga Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Nanjing’s 50.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Nanjing

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Nanjing's Innovation Score is 50.5/100 (top 13% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Nanjing?

Each dot is one of Nanjing’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Nanjing’s own 21.3 claims/patent is ABOVE the 16.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Nanjing vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 15.915.91616.1 0510152025 Granted patents (volume) Avg claims / patent Nuclera Ltd - 16, 15NucleraNugen Technologies, Inc. - 16, 21.94NugenNZ Tube Mills Limited - 16, 5.06NZ Tube MillsNamuga Co., Ltd. - 16, 15.06NamugaNanotech Energy, Inc. - 16, 19.62Nanotech EnergyNectar, Inc. - 16, 17.44NectarNeozyme International, Inc. - 16, 19.12Neozyme Internati…Neurolens, Inc. - 16, 16.81NeurolensNanjing Legend Biotech Co., Ltd - 16, 21.31Nanjing Legend Bi…
Nanjing vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Nanjing's grants concentrate

Nanjing Legend Biotech Co., Ltd is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2023 (5 grants) versus a trough of 1 in 2019. By volume, Nanjing sits between Nuclera Ltd and Neurolens, Inc..

Nanjing's three-year grant acceleration

Nanjing Legend Biotech Co., Ltd shows 13 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Nanjing's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Nanjing holds 16 patents at rank #17,943, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Nanjing

By rank, the assignees closest to #17,943 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Nanjing's primary technology class.

Nanjing's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

50 Top 13% higher than 87% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0123456 201920212022202320242025 1
USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table
Nanjing Legend Biotech Co., Ltd patent grants by year, 2015–2025
Year Patents Granted Share of Period
2019 1 6.3%
2021 1 6.3%
2022 4 25.0%
2023 5 31.3%
2024 4 25.0%
2025partial year 1 6.3%

Which technologies does Nanjing Legend Biotech Co., Ltd patent most?

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Nanjing Legend Biotech Co., Ltd's patent record in context - here's where to go next.

  • Nanjing Legend Biotech Co., Ltd's lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
  • Ranked #17,924 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Nanjing Legend Biotech Co., Ltd against Nuclera Ltd, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 50.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.